Effect of treatment regimen containing Bedaquiline for drug-resistant tuberculosis on the QT interval of electrocardiogram

doi:10.3969/j.issn.1004-583X.2024.07.008

Abstract

Abstract:

Objective To explore the effect of treatment regimen containing Bedaquiline for drug-resistant tuberculosis on the QT interval of electrocardiogram. Methods A total of 204 patients with drug-resistant tuberculosis admitted in the Department of Tuberculosis, Kunming Third People's Hospital from August 2018 to December 2022 were selected. Eighty-four patients treated with Bedaquiline-containing regimen were included in the observation group. After excluding 4 dropouts and 2 deaths, 78 cases were finally included in the observation group. A total of 120 patients treated with the regimen without Bedaquiline were enrolled in the control group, and finally 115 were eligible (4 dropouts and 1 death).The QT interval and clinical data of two groups at different stages of treatment were compared. Results Compared with the baseline, the QT interval of electrocardiogram in the observation group was significantly higher at the 2 nd, 4 th, 8 th, 12 th, 16 th, 20 th and 24 th weeks of treatment significantly (P<0.05). The QT period of the observation group was significantly longer than that of the control group at the 16 th, 20 th and 24 th week of treatment(P<0.05). In the observation group, there were 15 cases (19.2%, 15/78 ) with QT interval greater than 500 ms, including 7 cases of background regimen containing clofazimine and moxifloxacin. Conclusion Treatment regimen containing Bedaquiline for drug-resistant tuberculosis prolongs QT interval, but the background regimen containing Clofazimine and Quinolones aggravates the prolonged QT interval. Therefore, electrocardiogram monitoring and cardiac examination should be strengthened when using betamethasone in combination with Clofazimine and Quinolones.

Key words: tuberculosis, multidrug-resistant, QT interval prolongation, bedaquiline, clofazimine, quinolone

CLC Number:

Wan Rong, Li Guangmei, Ji Yongjing, Liu Lei, Cui Cancan, Li Mingwu. Effect of treatment regimen containing Bedaquiline for drug-resistant tuberculosis on the QT interval of electrocardiogram[J]. Clinical Focus, 2024, 39(7): 630-634.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.07.008

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I7/630

Figures/Tables 3

Tab.1 General information between groups

项目	观察组( $n$ =78)	对照组( $n$ =115)	χ²值	P值
性别[例(%)]
男女	45(57.6) 33(42.4)	64(55.6) 51(44.4)	0.079	0.779
耐药类型[例(%)]
RR-TB	4(5.1)	18(15.7)	5.097	0.024
MDR-TB	34(43.6)	68(59.1)	4.505	0.034
Pre-XDR-TB	29(37.2)	24(20.9)	6.207	0.013
XDR-TB	11(14.1)	5(4.3)	5.817	0.016
治疗史[例(%)]
初治复治	29(37.2) 49(62.8)	41(35.7) 74(64.3)	0.047	0.829
背景方案[例(%)]
左氧氟沙星	2(2.6)	11(9.6)	3.626	0.057
莫西沙星	4(5.1)	15(13.0)	3.281	0.070
氯法齐明	22(28.2)	29(25.2)	0.213	0.644
左氧氟沙星+氯法齐明	19(24.4)	26(22.6)	0.080	0.778
莫西沙星+氯法齐明	15(19.2)	34(29.6)	2.620	0.105
QT间期>500 ms[例(%)]
背景方案为左氧氟沙星	0	0
背景方案为莫西沙星	0	0
背景方案为氯法齐明	4(4/22, 18.2)	1(1/29, 3.4)	3.071	0.080
背景方案为左氧氟沙星+氯法齐明	4(4/19, 21.1)	1(1/26, 3.8)	3.291	0.070
背景方案为莫西沙星+氯法齐明	7(7/15, 46.7)	2(2/34, 5.9)	11.546	0.001

Tab.1 General information between groups

项目	观察组( $n$ =78)	对照组( $n$ =115)	χ²值	P值
性别[例(%)]
男女	45(57.6) 33(42.4)	64(55.6) 51(44.4)	0.079	0.779
耐药类型[例(%)]
RR-TB	4(5.1)	18(15.7)	5.097	0.024
MDR-TB	34(43.6)	68(59.1)	4.505	0.034
Pre-XDR-TB	29(37.2)	24(20.9)	6.207	0.013
XDR-TB	11(14.1)	5(4.3)	5.817	0.016
治疗史[例(%)]
初治复治	29(37.2) 49(62.8)	41(35.7) 74(64.3)	0.047	0.829
背景方案[例(%)]
左氧氟沙星	2(2.6)	11(9.6)	3.626	0.057
莫西沙星	4(5.1)	15(13.0)	3.281	0.070
氯法齐明	22(28.2)	29(25.2)	0.213	0.644
左氧氟沙星+氯法齐明	19(24.4)	26(22.6)	0.080	0.778
莫西沙星+氯法齐明	15(19.2)	34(29.6)	2.620	0.105
QT间期>500 ms[例(%)]
背景方案为左氧氟沙星	0	0
背景方案为莫西沙星	0	0
背景方案为氯法齐明	4(4/22, 18.2)	1(1/29, 3.4)	3.071	0.080
背景方案为左氧氟沙星+氯法齐明	4(4/19, 21.1)	1(1/26, 3.8)	3.291	0.070
背景方案为莫西沙星+氯法齐明	7(7/15, 46.7)	2(2/34, 5.9)	11.546	0.001

Tab.2 QT intervals between groups( x -±s,ms)

治疗时间 (周)	观察组		对照组		$t$ 值	P值
治疗时间 (周)	例数	QT间期	例数	QT间期	$t$ 值	P值
0	78	424.99±24.35	115	414.15±17.01	2.101	0.182
2	75	440.77±25.99^*	113	443.25±24.45	0.412	0.486
4	75	446.20±30.78^*	112	441.54±29.19	0.508	0.792
8	74	453.81±30.38^*	112	441.47±16.13	1.738	0.115
12	72	452.07±36.44^*	110	435.69±19.55	1.822	0.081
16	69	450.93±30.15^*	110	435.23±16.14	3.737	<0.001
20	65	451.74±28.51^*	110	431.29±27.60	4.783	<0.001
24	68	457.69±26.46^*	110	436.00±24.13	1.939	0.031

Tab.2 QT intervals between groups( x -±s,ms)

治疗时间 (周)	观察组		对照组		$t$ 值	P值
治疗时间 (周)	例数	QT间期	例数	QT间期	$t$ 值	P值
0	78	424.99±24.35	115	414.15±17.01	2.101	0.182
2	75	440.77±25.99^*	113	443.25±24.45	0.412	0.486
4	75	446.20±30.78^*	112	441.54±29.19	0.508	0.792
8	74	453.81±30.38^*	112	441.47±16.13	1.738	0.115
12	72	452.07±36.44^*	110	435.69±19.55	1.822	0.081
16	69	450.93±30.15^*	110	435.23±16.14	3.737	<0.001
20	65	451.74±28.51^*	110	431.29±27.60	4.783	<0.001
24	68	457.69±26.46^*	110	436.00±24.13	1.939	0.031

Tab.3 Clinical characteristics of 15 patients with a QT interval more than 500 ms in the observation group

编号	性别	年龄	影响QT间期延长药物	电解质钾水平(mmol/L)	是否合并心脏病患	基线QT 间期	QTC 峰值	QT间期峰值时间点	治疗过程
1	女	32	氯法齐明	4.62	否	437	505	4周	腰椎结核,脓液MDR-TB药,后未超500 ms,完成贝达喹啉24周
2	男	44	氯法齐明	3.94	否	427	565	8周	肺结核,Pre-XDR-TB,经停药,也有超500 ms,间断服药完成贝达喹啉24周
3	女	48	氯法齐明	3.97	否	425	505	8周	肺结核,Pre-XDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
4	男	59	氯法齐明	4.11	否	441	517	8周	肺结核,Pre-XDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
5	男	57	氯法齐明+左氧氟沙星	4.17	否	435	519	8周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
6	男	52	氯法齐明+左氧氟沙星	3.87	否	430	557	12周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
7	女	29	氯法齐明+左氧氟沙星	3.35	有先心病	417	505	12周	肺结核,MDR-TB,有先心病病史血钾偏低,经停药,后反复试药无法继续贝达喹啉,未完成贝达喹啉24周,更改方案
8	男	43	氯法齐明+左氧氟沙星	4.66	否	450	512	12周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
9	女	24	氯法齐明+莫西沙星	3.83	否	438	505	20周	肺结核,MDR-TB,经停药,后通过换掉氯法齐明,未超500 ms,完成贝达喹啉24周
10	男	27	氯法齐明+莫西沙星	3.65	否	423	518	4周	肺结核,颈淋巴结结核,培养示Pre-XDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
11	女	46	氯法齐明+莫西沙星	3.83	否	440	597	12周	肺结核,MDR-TB,经停药,后反复试药无法继续贝达喹啉,未完成贝达喹啉24周,更改方案
12	女	33	氯法齐明+莫西沙星	4.04	否	445	507	2周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
13	男	44	氯法齐明+莫西沙星	4.04	否	431	508	16周	肺结核,MDR-TB,经停药,后反复试药无法继续贝达喹啉,未完成贝达喹啉24周,更改方案
14	女	35	氯法齐明+莫西沙星	3.32	否	437	518	20周	肺结核,结核性脑炎,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
15	男	56	氯法齐明+莫西沙星	3.44	否	433	527	12周	肺结核,胸椎结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周

Tab.3 Clinical characteristics of 15 patients with a QT interval more than 500 ms in the observation group

编号	性别	年龄	影响QT间期延长药物	电解质钾水平(mmol/L)	是否合并心脏病患	基线QT 间期	QTC 峰值	QT间期峰值时间点	治疗过程
1	女	32	氯法齐明	4.62	否	437	505	4周	腰椎结核,脓液MDR-TB药,后未超500 ms,完成贝达喹啉24周
2	男	44	氯法齐明	3.94	否	427	565	8周	肺结核,Pre-XDR-TB,经停药,也有超500 ms,间断服药完成贝达喹啉24周
3	女	48	氯法齐明	3.97	否	425	505	8周	肺结核,Pre-XDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
4	男	59	氯法齐明	4.11	否	441	517	8周	肺结核,Pre-XDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
5	男	57	氯法齐明+左氧氟沙星	4.17	否	435	519	8周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
6	男	52	氯法齐明+左氧氟沙星	3.87	否	430	557	12周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
7	女	29	氯法齐明+左氧氟沙星	3.35	有先心病	417	505	12周	肺结核,MDR-TB,有先心病病史血钾偏低,经停药,后反复试药无法继续贝达喹啉,未完成贝达喹啉24周,更改方案
8	男	43	氯法齐明+左氧氟沙星	4.66	否	450	512	12周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
9	女	24	氯法齐明+莫西沙星	3.83	否	438	505	20周	肺结核,MDR-TB,经停药,后通过换掉氯法齐明,未超500 ms,完成贝达喹啉24周
10	男	27	氯法齐明+莫西沙星	3.65	否	423	518	4周	肺结核,颈淋巴结结核,培养示Pre-XDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
11	女	46	氯法齐明+莫西沙星	3.83	否	440	597	12周	肺结核,MDR-TB,经停药,后反复试药无法继续贝达喹啉,未完成贝达喹啉24周,更改方案
12	女	33	氯法齐明+莫西沙星	4.04	否	445	507	2周	肺结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
13	男	44	氯法齐明+莫西沙星	4.04	否	431	508	16周	肺结核,MDR-TB,经停药,后反复试药无法继续贝达喹啉,未完成贝达喹啉24周,更改方案
14	女	35	氯法齐明+莫西沙星	3.32	否	437	518	20周	肺结核,结核性脑炎,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周
15	男	56	氯法齐明+莫西沙星	3.44	否	433	527	12周	肺结核,胸椎结核,MDR-TB,经停药,后未超500 ms,完成贝达喹啉24周

References 20

[1]	World Health Organization. Global tuberculosis report 2023[EB/OL]. 2023.
[2]	Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis[J]. Eur Respir J, 2016, 47(2):564-574.
[3]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志, 2019, 41(10):1025-1073.
[4]	Cox E, Laessig K. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis[J]. N Engl J Med, 2014, 371(8):689-691.
[5]	WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update[R/OL]. Geneva: World Health Organization, 2022.
[6]	Postema PG, Wilde AA. The measurement of the QT interval[J]. Curr Cardiol Rev, 2014, 10(3):287-294. doi: 10.2174/1573403x10666140514103612 pmid: 24827793
[7]	谢莉, 朱慧, 高静韬, 等. 贝达喹啉血药浓度在耐药肺结核治疗中的变化及其与QTc间期延长的相关性[J]. 中国防痨杂志, 2022, 44(3):219-226.
[8]	谢莉, 高静韬, 马丽萍, 等. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响[J]. 中国防痨杂志, 2020, 42(7):687-694.
[9]	Darmayani IGAAPS, Ascobat P, Instiaty I, et al. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data[J]. Acta Med Indones. 2022, 54(3):389-396. pmid: 36156479
[10]	梁丽, 邹莉萍, 袁平, 等. 贝达喹啉与其他致QT间期延长药物联合应用对耐多药肺结核患者QT间期的影响[J]. 中国感染与化疗杂志, 2022, 22(5):563-569. doi: 10.16718/j.1009-7708.2022.05.007
[11]	Li R, Ma JB, Yang H, et al. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study[J]. Microbiol Spectr, 2023, 13:e0104823.
[12]	Ali AM, Radtke KK, Hesseling AC, et al. QT interval prolongation with one or more QT-prolonging agents used as part of a multidrug regimen for rifampicin-resistant tuberculosis treatment: Findings from two pediatric studies[J]. Antimicrob Agents Chemother, 2023, 67(7):e0144822.
[13]	World Health Organization. WHO conso1idated guidelines on drug-resistant tuberculosis treatment[R]. Geneva: World Health Organization, 2019.
[14]	Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine[J]. Eur Respir J, 2016, 48(5):1527-1529. doi: 10.1183/13993003.01552-2016 pmid: 27799401
[15]	李陆, 文靓, 房德敏, 等. 喹诺酮类药物致QT间期延长的系统性回顾分析[J]. 天津药学, 2019, 31(2):15-21.
[16]	肖丹丹, 赵广阔, 陈敏. 莫西沙星致不良反应134例文献分析[J]. 中国药物应用与监测, 2019, 16(5):287-291.
[17]	Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management[J]. Can Pharm J (Ott), 2016, 149(3):139-152.
[18]	Hincapie-Castillo JM, Staley B, Henriksen C, et al. Development of a predictive model for drug-associated QT prolongation in the inpatient setting using electronic health record data[J]. Am J Health Syst Pharm, 2019, 76(14):1059-1070.
[19]	中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版)[J]. 中华结核和呼吸杂志, 2021, 44(2):81-87.
[20]	Maartens G, Brill MJE, Pandie M, et al. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis[J]. Int J Tuberc Lung Dis, 2018, 22(1):26-29. doi: 10.5588/ijtld.17.0615 pmid: 29145924